Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats

Radiopharmaceuticals for Relapsed or Refractory Leukemias

(2019) Charles A. Kunos et al.   Frontiers in Oncology

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

(2019) Nicholas C. Richardson et al.   ONCOLOGIST

Taking a "BiTE out of ALL" - Blinautmomab approval for MRD positive ALL

(2019) Emily Curran et al.   BLOOD

Targeting CLL-1 for acute myeloid leukemia therapy

(2019) Hongbing Ma et al.   Journal of Hematology & Oncology

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention

(2019) Zvi Fishelson et al.   Frontiers in Immunology

Safety and Efficacy of Escalating Doses of 90 Y-BC8-DOTA (Anti-CD45) Followed by Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Chemotherapy and Autologous Stem Cell Transplantation (ASCT) for High-Risk Lymphoma

(2018) Ryan D. Cassaday et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

CD157: From immunoregulatory protein to potential therapeutic target

(2018) Erika Ortolan et al.   IMMUNOLOGY LETTERS

CD45 in human physiology and clinical medicine

(2018) Andreas Rheinländer et al.   IMMUNOLOGY LETTERS

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

(2018) Jeffrey E. Lancet et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab

(2018) Ahmed T. Kurdi et al.   MOLECULAR CANCER THERAPEUTICS

CD99 at the crossroads of physiology and pathology

(2018) Michela Pasello et al.   Journal of Cell Communication and Signaling

Therapeutic Antibodies for Myeloid Neoplasms—Current Developments and Future Directions

(2018) Christian M. Schürch   Frontiers in Oncology

Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial

(2018) Juliette Lambert et al.   HAEMATOLOGICA

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

(2018) Courtney D. DiNardo et al.   BLOOD

FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia

(2018) Aviva C Krauss et al.   CLINICAL CANCER RESEARCH

Cytarabine and daunorubicin for the treatment of acute myeloid leukemia

(2017) Tracy Murphy et al.   EXPERT OPINION ON PHARMACOTHERAPY

CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27 kip1 signaling

(2017) Feifei Zhang et al.   HAEMATOLOGICA

Pyrrolobenzodiazepine Dimer Antibody–Drug Conjugates: Synthesis and Evaluation of Noncleavable Drug-Linkers

(2017) Stephen J. Gregson et al.   JOURNAL OF MEDICINAL CHEMISTRY

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation

(2017) Richard M. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting CD157 in AML using a novel, Fc-engineered antibody construct

(2017) Christina Krupka et al.   Oncotarget

Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review

(2017) Tiantian Li et al.   Theranostics

CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27 kip1 signaling

(2017) Feifei Zhang et al.   HAEMATOLOGICA

Phase I trial of the targeted alpha-particle nano-generator actinium-225 (225Ac-lintuzumab) (anti-CD33; HuM195) in acute myeloid leukemia (AML).

(2017) J. G. Jurcic et al.   JOURNAL OF CLINICAL ONCOLOGY

Decitabine enhances anti-CD33 monoclonal antibody BI 836858-mediated natural killer ADCC against AML blasts

(2016) S. Vasu et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Antibody-drug conjugates—an emerging class of cancer treatment

(2016) Nikolaos Diamantis et al.   BRITISH JOURNAL OF CANCER

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia

(2016) U. Reusch et al.   CLINICAL CANCER RESEARCH

Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy

(2016) S. J. Blake et al.   CLINICAL CANCER RESEARCH

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function

(2016) D. A. Vallera et al.   CLINICAL CANCER RESEARCH

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond

(2016) Niels W. C. J. van de Donk et al.   IMMUNOLOGICAL REVIEWS

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics

(2016) Niloufar Ataie et al.   JOURNAL OF MOLECULAR BIOLOGY

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting

(2016) Kejie Zhang et al.   Oncotarget

Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform

(2015) M. Al-Hussaini et al.   BLOOD

Anti-CD45 radioimmunotherapy without TBI before transplantation facilitates persistent haploidentical donor engraftment

(2015) J. J. Orozco et al.   BLOOD

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

(2015) Alan K. Burnett et al.   BLOOD

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

Targeted inhibition of genome-wide DNA methylation analysis in epigenetically modulated phenotypes in lung cancer

(2015) Shou-Ping Dai et al.   MEDICAL ONCOLOGY

Alternative molecular formats and therapeutic applications for bispecific antibodies

(2015) Christoph Spiess et al.   MOLECULAR IMMUNOLOGY

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1

(2015) Tao Dao et al.   NATURE BIOTECHNOLOGY

The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk

(2015) Kimberly H. Harrington et al.   PLoS One

Radiation sensitivity of human and murine peripheral blood lymphocytes, stem and progenitor cells

(2014) Daniel Heylmann et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

(2014) Raya Mawad et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

(2014) B. Gyurkocza et al.   BLOOD

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets

(2014) M. K. Gleason et al.   BLOOD

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

(2014) J. E. Lancet et al.   BLOOD

Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML

(2014) Jorge E. Cortes et al.   CANCER

Bispecific T-cell engagers for cancer immunotherapy

(2014) Amelia M Huehls et al.   IMMUNOLOGY AND CELL BIOLOGY

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

(2014) Simon Z. He et al.   LEUKEMIA & LYMPHOMA

MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131− epitope expressed by leukemia stem cells

(2014) Jeffrey V. Leyton et al.   LEUKEMIA RESEARCH

Preclinical Characterization of AMG 330, a CD3/CD33-Bispecific T-Cell-Engaging Antibody with Potential for Treatment of Acute Myelogenous Leukemia

(2014) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia

(2013) S. H. Petersdorf et al.   BLOOD

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML

(2013) G. S. Laszlo et al.   BLOOD

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16 x 33 Bispecific Killer Cell Engager and ADAM17 Inhibition

(2013) A. Wiernik et al.   CLINICAL CANCER RESEARCH

Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation

(2013) Rainer Storb et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial

(2013) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system

(2013) C Arndt et al.   LEUKEMIA

Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

(2013) C Arndt et al.   LEUKEMIA

CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21)

(2013) Noriyoshi Iriyama et al.   LEUKEMIA RESEARCH

Involvement of CD244 in Regulating CD4+ T Cell Immunity in Patients with Active Tuberculosis

(2013) Bingfen Yang et al.   PLoS One

How I treat pediatric acute myeloid leukemia

(2012) J. E. Rubnitz   BLOOD

IL-1 receptor 2 (IL-1R2) and its role in immune regulation

(2012) Vanessa A. Peters et al.   BRAIN BEHAVIOR AND IMMUNITY

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

(2012) M. A. Sekeres et al.   HAEMATOLOGICA

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

(2012) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct

(2012) M Aigner et al.   LEUKEMIA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells

(2012) S.-R. Kuo et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Human NK cell lytic granules and regulation of their exocytosis

(2012) Konrad Krzewski et al.   Frontiers in Immunology

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia

(2011) J.-H. Lee et al.   BLOOD

Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells

(2011) Marion Piedfer et al.   FASEB JOURNAL

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Auger Electron Radioimmunotherapeutic Agent Specific for the CD123+/CD131- Phenotype of the Leukemia Stem Cell Population

(2011) J. V. Leyton et al.   JOURNAL OF NUCLEAR MEDICINE

Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module

(2011) Slava Stamova et al.   MOLECULAR IMMUNOLOGY

Stem cell gene expression programs influence clinical outcome in human leukemia

(2011) Kolja Eppert et al.   NATURE MEDICINE

High Proportion of Leukemic Stem Cells at Diagnosis Is Correlated with Unfavorable Prognosis in Childhood Acute Myeloid Leukemia

(2011) Kai-Erik Witte et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Potentiation of lysis of leukaemia cells by a bispecific antibody to CD33 and CD16 (FcγRIII) expressed by human natural killer (NK) cells

(2010) Lucia M. R. Silla et al.   BRITISH JOURNAL OF HAEMATOLOGY

A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting

(2010) Markus Kügler et al.   BRITISH JOURNAL OF HAEMATOLOGY

TIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells

(2010) Yoshikane Kikushige et al.   Cell Stem Cell

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16

(2010) Heiko Singer et al.   JOURNAL OF IMMUNOTHERAPY

Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

(2010) R Handgretinger et al.   LEUKEMIA

Radiation-induced cell death mechanisms

(2010) David Eriksson et al.   TUMOR BIOLOGY

Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome

(2009) J. M. Pagel et al.   BLOOD

Anthracycline Dose Intensification in Acute Myeloid Leukemia

(2009) Hugo F. Fernandez et al.   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia

(2009) Bob Löwenberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells

(2008) D. C. Taussig et al.   BLOOD

Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences

(2008) V. Kersemans et al.   JOURNAL OF NUCLEAR MEDICINE

Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly

(2008) J. Laubach et al.   ONCOLOGIST

Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology

(2008) Fabio Malavasi et al.   PHYSIOLOGICAL REVIEWS

The moonlighting enzyme CD13: old and new functions to target

(2008) Paola Mina-Osorio   TRENDS IN MOLECULAR MEDICINE